
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
Argenx has demonstrated a strong outlook driven by the robust performance of its lead product, Vyvgart, which is experiencing continued growth from the PFS launch, evidenced by a 20% year-over-year increase in new prescribers. The company's recent FDA approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, along with positive Phase 3 results for ocular myasthenia gravis, highlights significant expansion opportunities that could enhance the product's market presence and increase the accessible patient population. Additionally, the successful results from the ADAPT studies reinforce the company's innovative pipeline and bolster confidence in the commercial viability of its therapies, positioning Argenx favorably within the biopharmaceutical landscape.
Bears say
Argenx's outlook reflects significant concerns due to potential delays in obtaining necessary regulatory approvals, which could adversely affect the company's share price. The inherent risks associated with clinical trials pose a threat to the efficacy of argenx’s lead assets and future drug candidates, potentially limiting their market viability. Additionally, the competitive landscape for autoimmune and oncologic diseases is intensifying, as argenx must contend with both established and emerging players offering similar therapeutic options, diminishing its market position.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares